Navigation Links
Pharmaxis Long-Term Safety Study of Bronchitol Completes
Date:6/11/2008

Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

CONTACT:

Alan Robertson

Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Released through:

Australia:

Virginia Nicholls

Tel: +61-417-610-824

Email: virginia.nicholls@pharmaxis.com.au

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgroup.com

Australia:

Felicity Moffatt

Tel: +61-418-677-701

Email: moffattf@healthpr.com


'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Research and ... Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market ... For the purposes of this report, the human microbiome ... The human microbiome market is expected to be valued ... at a CAGR of 22.3% within the forecast period of ...
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... PLEASANTON, Calif., Oct. 28 Thoratec Corporation (Nasdaq: ... circulatory support therapies to save, support and restore failing ... quarter of 2010 increased 40 percent versus the third ... for both the third quarter and first nine months ...
... (NYSE: RMD ) today announced record revenue and ... the quarter ended September 30, 2010 was $282.0 million, a ... over the quarter ended September 30, 2009.  For the quarter ... and net income was $56.7 million, an increase of 26% ...
Cached Medicine Technology:Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 2Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 3Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 4Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 6Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 7Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 8Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 9Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 10Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 11Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 12Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 13Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 14Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 15Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 16ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 2ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 3ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 4ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 5ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 6
(Date:9/21/2014)... United-Kingdom (PRWEB) September 22, 2014 PhUSE ... Sweeney and Dr. Lilliam Rosario as keynote speakers for ... Following keynotes from Dr. Ben Goldacre in 2013 ... Professor Lord Winston in 2011 , PhUSE again presents ... who are passionate about advancement of clinical information. , ...
(Date:9/21/2014)... September 21, 2014 Expert witness work ... the findings from its 2014 Expert Witness Fees & ... complex, the demand and compensation for qualified and credentialed ... the Survey’s 16-year history. , The nearly 600 ... for their expert work, an increase of 3.2% from ...
(Date:9/21/2014)... September 21, 2014 Over the past ... drugs to inundate the market, thereby cutting into revenue ... industry. According to data from Industry Canada, the loss ... industry $1.8 and $2.5 billion in 2010 and 2012, ... patent exclusivity, which has hampered revenue growth, many pharmaceutical ...
(Date:9/21/2014)... understand why cancer cells metastasize? Think of Sparta. , ... better prepared them for the demands of battle on ... same thing according to a new study revealing previously ... at the original tumor site, and those that travel ... unyielding ability to metastasize is the primary cause of ...
(Date:9/21/2014)... 21, 2014 Hundreds of Risperdal ... in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein ... proceeding’s next monthly meeting has been scheduled for ... , “Our Firm is representing a number of ... litigation. We are pleased with its continued progress,” ...
Breaking Medicine News(10 mins):Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4
... Demand for Dark Chocolate by Active, On-the-Go Consumers , , ... Fueled by demand for nutritious, yet delicious snacks, Abbott ... ZonePerfect (R) Dark Chocolate Nutrition Bars - Dark ... Creme. , , Made with real cacao, ZonePerfect ...
... YORK, June 2 , ... 1991 , PharmaPendium ( http://www.info.pharmapendium.com/ ... drug,information, has significantly expanded its coverage of US Food ... the FDA Classic,Collection. This collection contains all available historical ...
... for Focus, Performance and Recovery , , HUNTINGTON BEACH, ... high-performance sports water designed ... to give them an edge, in terms of focus, better ... , , "With AquaHydrate, we believe ...
... be used to perform several screens, researchers say , TUESDAY, ... stool can accurately screen for more types of cancer than ... DNA stool testing has been successfully used for early detection ... that the noninvasive screening is also good at finding other ...
... researchers have demonstrated that a noninvasive screening test can detect ... the colon -- including pancreas, stomach, biliary and esophageal cancers. ... being presented at Digestive Disease Week 2009 in Chicago, May ... for approximately one in four cancer deaths. While high cure ...
... 2 June 2009 -- PharmaPendium ( http://www.info.pharmapendium.com ), ... drug information, has significantly expanded its coverage of US ... launch of the FDA Classic Collection. This collection contains ... including those issued in 1991 all indexed and ...
Cached Medicine News:Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 2Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 3Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 4Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 2Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 3Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 2Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 3Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 4Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 3Health News:Elsevier's PharmaPendium introduces the FDA Classic Collection 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: